PDCD1 and pachyonychia congenita: Monotherapy with immune checkpoint inhibitors targeting CTLA-4 and the programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1)) has mostly failed to elicit efficacy in patients with PC [88,89].